Shukla Shiva K, Gaudriault Pierre, Corbera Antoni
Research and Development Unit, Beez Biotech SAS, RENNES, Ille-et-Villain, 35000, France.
Research and Development Unit, Cherry Biotech SAS, Paris, 93100, France.
Open Res Eur. 2023 Oct 30;3:188. doi: 10.12688/openreseurope.16671.1. eCollection 2023.
Quality sperm selection is essential to ensure the effectiveness of assisted reproductive techniques (ART). However, the methods employed for sperm selection in ART often yield suboptimal outcomes, contributing to lower success rates. In recent years, microfluidic devices have emerged as a promising avenue for investigating the natural swimming behavior of spermatozoa and developing innovative approaches for quality sperm selection. Despite their potential, the commercial translation of microfluidic-based technologies has remained limited. This comprehensive review aims to critically evaluate the inherent potential of lab-on-chip technology in unraveling sophisticated mechanisms encompassing rheotaxis, thermotaxis, and chemotaxis. By reviewing the current state-of-the-art associated with microfluidic engineering and the swimming of spermatozoa, the goal is to shed light on the multifaceted factors that have impeded the broader commercialization of these cutting-edge technologies and recommend a commercial that can surmount the prevailing constraints. Furthermore, this scholarly exploration seeks to enlighten and actively engage reproductive clinicians in the profound potential and implications of microfluidic methodologies within the context of human infertility.
优质精子的筛选对于确保辅助生殖技术（ART）的有效性至关重要。然而，ART中用于精子筛选的方法往往效果欠佳，导致成功率较低。近年来，微流控装置已成为研究精子自然游动行为以及开发优质精子筛选创新方法的一条有前景的途径。尽管具有潜力，但基于微流控的技术在商业转化方面仍然有限。本综述旨在批判性地评估芯片实验室技术在揭示包括趋流性、趋温性和趋化性等复杂机制方面的内在潜力。通过回顾与微流控工程和精子游动相关的当前技术水平，目标是阐明阻碍这些前沿技术更广泛商业化的多方面因素，并推荐一种能够克服现有限制的商业化方案。此外，这一学术探索旨在启发生殖临床医生，并让他们积极参与到微流控方法在人类不孕症背景下的巨大潜力和影响中来。
